Menopause Relief: A testosterone patch to be tested in a clinical trial

Menopause

The testosterone patch is a new treatment option for women who experience low sexual desire and other symptoms of menopause. The patch delivers a low dose of testosterone through the skin, miming the natural production of the hormone in the ovaries. Testosterone is essential not only for sexual function but also for mood, energy, bone health, and cognitive function.

Why is the testosterone patch needed?

Many women experience a decline in testosterone levels as they approach menopause. This can lead to losing libido, sexual satisfaction, confidence, and well-being. Current treatments for menopausal symptoms, such as hormone replacement therapy (HRT), do not address the issue of low testosterone. Some forms of HRT may further lower testosterone levels. The testosterone patch aims to restore the hormonal balance and improve the quality of life of menopausal women.

See Also:  International Nurses Day 2023: The backbone of our healthcare system

What are the benefits and risks of the testosterone patch?

The testosterone patch has been shown to improve sexual desire, arousal, orgasm, and pleasure in women with low testosterone levels. It may also positively affect mood, energy, memory, and concentration. The patch is designed to deliver a physiological dose of testosterone similar to what the ovaries produce before menopause. Therefore, it is unlikely to cause side effects such as acne, hair growth, or voice changes associated with higher doses of testosterone. However, the long-term safety and efficacy of the patch are still unknown and need to be tested in clinical trials.

When will the testosterone patch be available?

The testosterone patch is undergoing phase 3 clinical trials in the UK and Australia reports The Guardian. These trials will involve more than 500 women who will use the patch for 12 months and compare it with a placebo. The results are expected to be published in 2024. If the trials are successful, the patch could be approved by regulatory authorities and become available by 2025.

ranjita shalgar
About S Ranjita 469 Articles
Ranjita is a seasoned writer on a variety of topics. She has been writing for 8 years now on various international publications. Entertainment and current news topics are her favorite. She can be reached at [email protected]

Be the first to comment

Leave a Reply

Your email address will not be published.